NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis $7.04 +0.25 (+3.68%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.86▼$7.1150-Day Range$5.58▼$7.0452-Week Range$5.47▼$15.70Volume1.10 million shsAverage Volume3.53 million shsMarket Capitalization$1.10 billionP/E RatioN/ADividend YieldN/APrice Target$18.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ironwood Pharmaceuticals alerts: Email Address Ironwood Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside161.4% Upside$18.40 Price TargetShort InterestHealthy10.89% of Float Sold ShortDividend StrengthN/ASustainability-2.94Upright™ Environmental ScoreNews Sentiment0.91Based on 7 Articles This WeekInsider TradingSelling Shares$425,748 Sold Last QuarterProj. Earnings Growth33.93%From $0.56 to $0.75 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.55 out of 5 starsMedical Sector97th out of 936 stocksPharmaceutical Preparations Industry35th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIronwood Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Ironwood Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.89% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 6.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIronwood Pharmaceuticals has received a 39.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Linaclotide" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ironwood Pharmaceuticals is -2.94. Previous Next 3.3 News and Social Media Coverage News SentimentIronwood Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ironwood Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest3 people have searched for IRWD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $425,748.00 in company stock.Percentage Held by Insiders12.90% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ironwood Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to grow by 33.93% in the coming year, from $0.56 to $0.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ironwood Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Read More IRWD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRWD Stock News HeadlinesJuly 25 at 8:44 PM | stockhouse.comIronwood Pharmaceuticals to Host Second Quarter 2024 Investor Update CallJuly 19, 2024 | msn.comImplied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock OptionsJuly 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.July 17, 2024 | americanbankingnews.comIronwood Pharmaceuticals (NASDAQ:IRWD) Upgraded by StockNews.com to "Buy"June 20, 2024 | seekingalpha.comIronwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBCMay 30, 2024 | businesswire.comIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceMay 22, 2024 | markets.businessinsider.comIronwood Pharma’s Apraglutide Poised for Blockbuster Status with Strong Phase 3 Results: A Buy RatingMay 21, 2024 | markets.businessinsider.comIronwood Pharmaceuticals’ Growth Potential Bolstered by Promising LINZESS and Apraglutide Clinical DataJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…May 21, 2024 | finance.yahoo.comIronwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)May 14, 2024 | msn.comIronwood Pharmaceuticals’ (NASDAQ:IRWD) Challenges Continue with Q1 MissesMay 12, 2024 | finance.yahoo.comUS$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest ResultsMay 11, 2024 | morningstar.comIronwood Pharmaceuticals Inc Class AMay 10, 2024 | finance.yahoo.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comIronwood Pharmaceuticals Reports Mixed Q1 2024 Results Amid Key Clinical AdvancementsMay 10, 2024 | markets.businessinsider.comIronwood Pharma’s Strong Commercial Execution and Promising Pipeline Support Buy RatingMay 9, 2024 | seekingalpha.comIronwood Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 9, 2024 | investorplace.comIRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024See More Headlines Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees267Year FoundedN/APrice Target and Rating Average Stock Price Target$18.40 High Stock Price Target$22.00 Low Stock Price Target$14.00 Potential Upside/Downside+165.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($6.79) Trailing P/E RatioN/A Forward P/E Ratio12.38 P/E GrowthN/ANet Income$-1,002,240,000.00 Net Margins-254.41% Pretax Margin-243.98% Return on Equity-28.45% Return on Assets18.84% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual Sales$442.73 million Price / Sales2.45 Cash FlowN/A Price / Cash FlowN/A Book Value($2.21) per share Price / Book-3.14Miscellaneous Outstanding Shares156,530,000Free Float136,337,000Market Cap$1.08 billion OptionableOptionable Beta0.52 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Thomas A. McCourt (Age 67)CEO & Director Comp: $1.61MMr. Sravan Kumar Emany (Age 46)Senior VP, Principal Financial Officer & CFO Comp: $913.88kMr. John Minardo (Age 48)Senior VP, Chief Legal Officer & Secretary Comp: $814.41kDr. Michael Shetzline M.D. (Age 65)Ph.D., Chief Medical Officer, Senior VP and Head of Research & Drug Development Comp: $860.45kMr. Andrew Davis (Age 37)Senior VP & Chief Business Officer Comp: $824.36kMr. Ronald Silver (Age 41)Corporate Controller & Principal Accounting Officer Mr. Marcel MoulaisonVice President of Technical OperationsGreg MartiniVice President of Strategic Finance & Investor RelationsMs. Beth CalitriHead of Corporate Communications & Media RelationsMr. Mike NanfitoVice President of Sales & Sales ExcellenceMore ExecutivesKey CompetitorsIGM BiosciencesNASDAQ:IGMSKura OncologyNASDAQ:KURACryoportNASDAQ:CYRXZentalis PharmaceuticalsNASDAQ:ZNTLMyovant SciencesNYSE:MYOVView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 28,921 shares on 7/26/2024Ownership: 0.032%Intrinsic Value Partners LLCSold 2,310 shares on 7/26/2024Ownership: 0.029%SummerHaven Investment Management LLCBought 2,491 shares on 7/24/2024Ownership: 0.046%Louisiana State Employees Retirement SystemBought 2,400 shares on 7/24/2024Ownership: 0.045%Gerber LLCBought 7,000 shares on 7/22/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions IRWD Stock Analysis - Frequently Asked Questions How have IRWD shares performed this year? Ironwood Pharmaceuticals' stock was trading at $11.44 at the beginning of 2024. Since then, IRWD stock has decreased by 38.5% and is now trading at $7.04. View the best growth stocks for 2024 here. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.18 by $0.20. The firm's revenue was down 28.0% compared to the same quarter last year. What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO? 7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' top institutional investors include Hennion & Walsh Asset Management Inc. (0.08%), Harbor Capital Advisors Inc. (0.07%), SummerHaven Investment Management LLC (0.05%) and Louisiana State Employees Retirement System (0.04%). Insiders that own company stock include Thomas A Mccourt, Mark G Currie, Jason Rickard, Michael Shetzline, Sravan Kumar Emany, Minardo John, Andrew Davis, Julie Mchugh, Jon R Duane, Ronald Silver, Catherine Moukheibir and Marla L Kessler. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH) and Allergan (AGN). This page (NASDAQ:IRWD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
